close

Minaris Regenerative Medicine will produce Mustang Bio’s MB107 lentiviral gene therapy for the treatment of SCID

 Minaris Regenerative Medicine will produce Mustang Bio's MB107 lentiviral gene therapy for the treatment of SCID Mustang Bio, a US clinical-stage biopharmaceutical company focused on cell and gene therapies for the treatment of hematologic cancers, solid tumors and rare genetic diseases, and Minaris Regenerative Medicine, a leading global contract development…..